(Q41611580)

5 October 2017

1 reference

title

Therapeutic options for severe pulmonary hypertension (English)

1 reference

5 October 2017

Palevsky HI

1

1 reference

5 October 2017

publication date

1 September 1997

1 reference

Clinics in Chest Medicine

5 October 2017

published in

1 reference

5 October 2017

volume

18

1 reference

5 October 2017

issue

3

1 reference

5 October 2017

page(s)

595-609

1 reference

Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease.

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Chronic major-vessel thromboembolic pulmonary artery obstruction: appearance at angiography

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Impact of pulmonary hypertension on outcome after single-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The role of thrombosis in severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The effect of digoxin on exercise capacity and exercising cardiac function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Haemodynamic effects of nifedipine, nitroglycerine and prazosin in pulmonary hypertension following ingestion of toxic oil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Vasodilators and primary pulmonary hypertension. Variability of long-term response

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostaglandins and pulmonary hypertension-further evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Acute respiratory failure of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Echo/Doppler and hemodynamic correlates of vasodilator responsiveness in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Management of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Long-term home oxygen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension: natural history and the importance of thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary thromboembolism: recent developments in diagnosis with CT and MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

A decade of lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

1 reference

7 January 2021

Pulmonary vasoconstriction due to nonocclusive distention of large pulmonary arteries in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Resting single-breath diffusing capacity as a screening test for exercise-induced hypoxemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Captopril in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Ventilation-Perfusion Inequalities During Graft Rejection in Patients Undergoing Single Lung Transplantation for Primary Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostacyclin and PGE1 treatment of pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short- and long-term evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Vasodilator therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Adverse effects of normovolemic polycythemia and hypoxia on hemodynamics in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Drug treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension. Immediate and long-term results in 42 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary angiography in severe chronic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The diffusing capacity as a predictor of arterial oxygen desaturation during exercise in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Deleterious effects of hydralazine in patients with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostacyclin and acetylcholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary veno-occlusive disease and its response to vasodilator agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Single lung transplantation for pulmonary hypertension. Single institution experience in 34 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary vasodilator effects of nitroglycerin and sodium nitroprusside in canine oleic acid-induced pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Acute hemodynamic effects of nitroglycerin in pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension. Responses to indomethacin, terbutaline, and isoproterenol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary arterial hypertension: value of perfusion scintigraphy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The role of thrombosis in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Pulmonary hypertension: a cellular basis for understanding the pathophysiology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Captopril as treatment for patients with pulmonary hypertension. Problem of variability in assessing chronic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Inhaled nitric oxide in persistent pulmonary hypertension of the newborn

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Inhaled nitric oxide for the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Factors that influence the outcome of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Oral hydralazine therapy for primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Primary Pulmonary Hypertension Treated with Oral Phentolamine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Platelet activation and fibrinopeptide formation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Fiberoptic angioscopy: role in the diagnosis of chronic pulmonary arterial obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Clinical course and late prognosis of treated subacute massive, acute minor, and chronic pulmonary thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Response of the pulmonary circulation to acetylcholine, calcitonin gene-related peptide, substance P and oral nicardipine in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The United States experience with the acute and chronic treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Chronic primary and secondary thromboembolic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Nitric oxide and the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970404-4

7 January 2021

10.1016/S0272-5231(05)70404-4

Identifiers

DOI

1 reference

5 October 2017

1 reference